Abstract 199P
Background
The homologous recombination deficiency (HRD) status has displayed the good predictive value for the survival and efficacy of ovarian cancer patients (OCs) received Olaparib in first-line therapy or after platinum-sensitive relapse (PSR). However, the efficacy and survival of Olaparib in some patients is dismal, in which the effective molecular biomarkers remain to be explored.
Methods
Total 60 patients (January 2016 to March 2021) received Olaparib (300 mg, BID) with or without Bevacizumab (7.5-15 mg/kg, once every 21 days) (PSR OCs, N=19; Non-PSR OCs, N = 41), and undergo HRD test by AmoyDx® HRD Focus Panel (HRD-positive, GSS score ≥ 50 or BRCA1/2 mutated). Through genomics and transcriptomics-based data, underlying mechanisms associated with efficacy and prognosis of 24 OCs with Olaparib treatment was identified. The primary endpoint was progression-free survival (long-PFS: > 12 months, short-PFS: ≤ 12 months).
Results
HRD status was determined in 60 OCs with received Olaparib. HRD was an independent prognosis factor (p = 0.029) according to the multivariate Cox regression analysis, and HRD-positive was correlated with longer PFS (p = 0.0064), especially for patients received Olaparib first-line therapy. High ICOSLG expression was associated with shorter PFS (p = 0.0073, AUC = 0.847). High co-expression of ICOSLG and DLX2, predicted higher recurrence rate (p = 0.01), and was verified as a predictive factor (ICOSLGhigh & DLX2high AUC = 0.81). Enrichment ratio of mast cells (MCs) was higher in the short-PFS group than in the long-PFS group (p = 0.053) with critical significance. A low percentage of dendritic cells (DCs) was significantly related to high recurrence rate (p = 0.033). High MCs and low DCs ratio signify an immunosuppressive microenvironment.
Conclusions
In the study, we confirmed that HRD-positive patients can benefit from Olaparib therapy, and have a good prognosis. ICOSLGhigh and ICOSLGhigh & DLX2high, as potential biomarkers of survival and Olaparib efficacy, may help to better identify patients who will benefit most from Olaparib treatment and require further validation in clinical studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial
Presenter: Yucheng Dong
Session: Poster session 08
103P - Epigenetic regulated genes enhanced fragmentomics-based model for early-stage lung cancer detection
Presenter: Yadong Wang
Session: Poster session 08
104P - The development of a classifier of somatic copy number alteration burden in liquid biopsy with potential clinical impact in advanced non-small cell lung cancer (NSCLC)
Presenter: Laura Bonanno
Session: Poster session 08
105P - Plasma ctDNA dynamics as clinical response biomarker for NSCLC: A systematic review and meta-analysis
Presenter: Luís Leite
Session: Poster session 08
106P - Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi)
Presenter: Laura Bonanno
Session: Poster session 08
107P - Germline pathogenic variants identified in tissue- and blood-based whole exome sequencing in advanced solid tumors
Presenter: Takeshi Kuwata
Session: Poster session 08
108P - Assessing molecular characteristics in a large cohort of anal squamous cell carcinoma patients
Presenter: Cristina Smolenschi
Session: Poster session 08
109P - Development and validation of a digital PCR assay for detection and monitoring of universally methylated circulating tumor DNA in patients with high-grade sarcoma
Presenter: Elisabeth Ashton
Session: Poster session 08
110P - 13-plex non-invasive genotyping in HPV related cancers in the MOSCATO trial
Presenter: Elise Rupp
Session: Poster session 08
111P - Leveraging circulating tumor DNA sequencing for first-line cancer treatment: Insights from two prospective precision medicine studies
Presenter: Veronique Debien
Session: Poster session 08